Search results for "bacteria."

showing 10 items of 4757 documents

Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

2014

Pseudomonas aeruginosa is the main pathogen in bronchopulmonary infections in cystic fibrosis (CF) patients. It can only be eradicated at early infection stages while reduction of its bacterial load is the therapeutic goal during chronic infection or exacerbations. Neonatal screening and pharmacokinetic/pharmacodynamic knowledge has modified the management of CF-patients. A culture based microbiological follow-up should be performed in patients with no infection with P. aeruginosa. At initial infection, inhaled colistin (0,5-2 MU/tid), tobramycin (300 mg/bid) or aztreonam (75 mg/tid) with or without oral ciprofloxacin (15-20 mg/kg/bid, 2-3 weeks) are recommended. In chronic infections, trea…

medicine.medical_specialtyCystic Fibrosismedicine.drug_classAntibioticsAztreonammedicine.disease_causeCystic fibrosisCystic fibrosischemistry.chemical_compoundInternal medicinemedicineTobramycinHumansPseudomonas InfectionsIntensive care medicinebusiness.industryPseudomonas aeruginosaGeneral Medicinemedicine.diseaseAntibiotic treatmentAnti-Bacterial AgentsCiprofloxacinChronic infectionchemistryChronic DiseasePseudomonas aeruginosaDisease ProgressionColistinbusinessBronchial infectionmedicine.drugArchivos de Bronconeumología (English Edition)
researchProduct

Oral Health Scales: Design of an Oral Health Scale of Infectious Potential

2013

Objectives: In this paper we propose a new Global Oral Health Scale that will allow the infectious potential of the oral cavity, clinically manifest as local and focal infections, to be condensed into a single parameter. Study Design: Based on a number of oral health scales previously designed by our group, we designed a final version that incorporates dental and periodontal variables (some of them evaluated using corroborated objective indices) that reflect the presence of caries and periodontal disease. Results: The application of the proposed oral health scale requires the examination of 6 sites per tooth (mesio- buccal, medio-buccal, disto-buccal, disto-lingual, medio-lingual and mesio-…

medicine.medical_specialtyDentistryOdontologíaOral HealthOral healthOral cavityRisk Assessmentstomatognathic systemPeriodontal diseaseEpidemiologyHumansMedicineGingival inflammationGeneral DentistryFinal versionbusiness.industrySingle parameterBacterial Infections:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludstomatognathic diseasesOtorhinolaryngologyScale (social sciences)UNESCO::CIENCIAS MÉDICASResearch-ArticleOdontostomatology for the Disabled or Special PatientsSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Review of European and American guidelines for the diagnosis of Lyme borreliosis

2019

International audience; Lyme disease is a tick-borne bacterial disease with polymorphic clinical manifestations (cutaneous, rheumatological, and neurological). In recent years the issue of the diagnosis of this infection has been highly publicized on the Internet and other media in Europe and America. Some patients and physicians may share the perception that the diagnosis of the infection is not reliable in France. We reviewed current European and American guidelines on Lyme disease and performed a methodological evaluation of all guidelines. We retrieved 16 guidelines from seven countries. Our analysis revealed a global consensus regarding diagnosis at each stage of the infection. All gui…

medicine.medical_specialtyDiagnostic methodsRecommandationsGuidelinesSerologyDiagnosis Differential03 medical and health sciencesLyme disease[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesBorreliamedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyComputingMilieux_MISCELLANEOUSLyme Disease[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesBacterial diseasebiology030306 microbiologyLyme borreliosisbusiness.industryBorreliabiology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyUnited States3. Good healthLYMEEuropeInfectious DiseasesFamily medicinePractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyLymeErythema migransbusinessMédecine et Maladies Infectieuses
researchProduct

Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in Fran…

2018

Background One of the major reasons to stop antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) in the United Kingdom but not in the rest of the world was that it would result in more deaths from fatal adverse drug reactions (ADRs) than the number of IE deaths. The main aim of this study was to quantify and describe the ADRs with amoxicillin or clindamycin for IE AP. The second aim was to infer a crude incidence of anaphylaxis associated with amoxicillin for IE AP. Material and Methods The Medical Dictionary for Regulatory Activities (MedDRA) was used to group ADRs for IE AP using the broad Standardized MedDRA Queries “Anaphylactic reaction, Amoxicillin, Clindamycin, Clostrid…

medicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsMedDRA03 medical and health sciences0302 clinical medicineInternal medicinePharmacovigilanceHumansMedicineEndocarditisAntibiotic prophylaxisGeneral DentistryOral Medicine and PathologyEndocarditisbusiness.industryResearchClindamycinEndocarditis Bacterial030206 dentistryAntibiotic ProphylaxisAmoxicillinClostridium difficilemedicine.disease:CIENCIAS MÉDICAS [UNESCO]3. Good healthOtorhinolaryngologyInfective endocarditisUNESCO::CIENCIAS MÉDICASSurgeryFrancebusinessmedicine.drug
researchProduct

Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction: a systematic revi…

2016

Background: Prophylactic use of amoxicillin and amoxicillin/clavulanic acid, although controversial, is common in routine clinical practice in third molar surgery. Material and Methods: Our objective was to assess the efficacy of prophylactic amoxicillin with or without clavulanic acid in reducing the incidence of dry socket and/or infection after third molar extraction. We conducted a systematic review and meta-analysis consulting electronic databases and references in retrieved articles. We included double-blind placebo-controlled randomized clinical trials published up to June 2015 investigating the efficacy of amoxicillin with or without clavulanic acid on the incidence of the aforement…

medicine.medical_specialtyDry SocketOdontologíaReviewTooth ExfoliationPlaceboAmoxicillin-Potassium Clavulanate Combinationlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawClavulanic acidInternal medicinemedicineHumansGeneral DentistryInfection Control030219 obstetrics & reproductive medicineAmoxicillin/clavulanic acidbusiness.industryAmoxicillin030206 dentistryAmoxicillinmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryAnti-Bacterial AgentsDry socketOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASNumber needed to treatSurgeryMolar ThirdAmoxicillin-Potassium Clavulanate CombinationOral Surgerybusinessmedicine.drug
researchProduct

Infective endocarditis triangle.. Is it the time to revisit infective endocarditis susceptibility and indications for its antibiotic prophylaxis?

2019

medicine.medical_specialtyEndocarditisEpidemiologybusiness.industryMEDLINEAntibiotic ProphylaxisGlobal HealthPrognosismedicine.diseaseAnti-Bacterial AgentsSurvival RateBacterial endocarditisInfective endocarditismedicineHumansAntibiotic prophylaxisCardiology and Cardiovascular MedicinebusinessIntensive care medicineEuropean Journal of Preventive Cardiology
researchProduct

PPI-based triple therapy in the eradication of H. pylori infection.

1999

medicine.medical_specialtyGastrointestinal DiseasesGastroenterologyHelicobacter InfectionsPharmacotherapyInternal medicinemedicineHumansEnzyme InhibitorsOmeprazoleHepatologybiologyHelicobacter pyloribusiness.industryAnti-ulcer AgentGastroenterologyProton Pump InhibitorsHelicobacter pyloriH pylori infectionHelicobacter Infectionsbiology.organism_classificationAnti-Ulcer AgentsAnti-Bacterial AgentsDrug Therapy CombinationbusinessOmeprazolemedicine.drugGastroenterology
researchProduct

Microbial technologies for the discovery of novel bioactive metabolites

2002

Soil microbes represent an important source of biologically active compounds. These molecules present original and unexpected structure and are selective inhibitors of their molecular targets. At Biosearch Italia, discovery of new bioactive molecules is mostly carried out through the exploitation of a proprietary strain collection of over 50000 strains, mostly unusual genera of actinomycetes and uncommon filamentous fungi. A critical element in a drug discovery based on microbial extracts is the isolation of unexploited groups of microorganisms that are at the same time good producers of secondary metabolites. Molecular genetics can assist in these efforts. We will review the development an…

medicine.medical_specialtyGenetic VectorsBioengineeringComputational biologyBiologySettore BIO/19 - Microbiologia Generalemedicine.disease_causeApplied Microbiology and BiotechnologyStreptomycesGenomePolymerase Chain ReactionMicrobiologySpecies SpecificityMolecular geneticsmedicineGeneEscherichia coliSoil MicrobiologyDrug discoveryGeneral MedicineGene Expression Regulation Bacterialbiology.organism_classificationIsolation (microbiology)ActinobacteriaGenetic VectorDirected Molecular EvolutionSoil microbiologyActinobacteria; Directed Molecular Evolution; Genetic Vectors; Polymerase Chain Reaction; Soil Microbiology; Species Specificity; Gene Expression Regulation BacterialBiotechnology
researchProduct

Efficacy of 1-week ranitidine-bismuth-citrate (RBC)-based triple therapy for eradication of Helicobacter pylori infection

1999

medicine.medical_specialtyHelicobacter pylori infectionRanitidineGastroenterologyHelicobacter InfectionsRanitidineMetronidazoleInternal medicineOrganometallic CompoundsmedicineHumansPharmacology (medical)Clinical Trials as TopicHelicobacter pyloriHepatologybiologybusiness.industryAnti-ulcer AgentGastroenterologyHelicobacter pyloriAnti-Ulcer AgentsHelicobacter Infectionsbiology.organism_classificationAnti-Bacterial AgentsMetronidazoleRanitidine HydrochlorideDrug Therapy CombinationAntacidsbusinessmedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

The impact of antibiotic resistance on the efficacy of three 7-day regimens againstHelicobacter pylori

2000

Background: Antibiotic resistance affects the success of anti-Helicobacter pylori therapies and varies greatly from country to country. Aim: To compare the efficacy of three short-term triple regimens in relation to H. pylori primary resistance in our region. Methods: We enrolled 210 H. pylori-positive dyspeptic patients for this randomized, open, parallel-group study. Three arms of 70 patients each received the following 1-week regimens: (1) ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (RCM); (2) bismuth subcitrate 240 mg b.d. + amoxycillin 1000 mg b.d. + metronidazole 500 mg b.d. (BAM); (3) omeprazole 20 mg o.d. + clarithromycin 250 mg b.…

medicine.medical_specialtyHepatologybiologybusiness.industryGastroenterologyDrug resistanceHelicobacter pyloriAmoxicillinbiology.organism_classificationGastroenterologySurgeryMetronidazoleBismuth SubcitrateClarithromycinInternal medicinemedicinePharmacology (medical)businessOmeprazolemedicine.drugAntibacterial agentAlimentary Pharmacology & Therapeutics
researchProduct